Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) received a $182.00 price target from equities research analysts at Piper Jaffray Companies in a research report issued on Friday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Piper Jaffray Companies’ target price indicates a potential upside of 17.13% from the stock’s previous close.

Several other analysts also recently weighed in on the company. Cowen and Company reiterated a “buy” rating and set a $190.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Friday. Mizuho downgraded Jazz Pharmaceuticals PLC from a “buy” rating to a “neutral” rating and dropped their price target for the company from $162.00 to $150.00 in a research note on Tuesday, July 4th. Leerink Swann boosted their price target on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Janney Montgomery Scott boosted their price target on Jazz Pharmaceuticals PLC from $138.00 to $175.00 and gave the company a “buy” rating in a research note on Tuesday, July 4th. Finally, Deutsche Bank AG reiterated a “buy” rating and set a $176.00 price target on shares of Jazz Pharmaceuticals PLC in a research note on Tuesday, July 4th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $182.56.

Shares of Jazz Pharmaceuticals PLC (JAZZ) traded up 0.59% on Friday, reaching $155.38. The company’s stock had a trading volume of 440,666 shares. Jazz Pharmaceuticals PLC has a 12-month low of $95.80 and a 12-month high of $163.75. The firm has a 50 day moving average price of $151.80 and a 200-day moving average price of $138.04. The stock has a market cap of $9.33 billion, a PE ratio of 23.48 and a beta of 1.11.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $1.41 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.42 by $0.01. Jazz Pharmaceuticals PLC had a net margin of 26.28% and a return on equity of 24.65%. The business had revenue of $376.10 million for the quarter, compared to analyst estimates of $376.58 million. During the same period in the prior year, the company earned $2.26 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Equities research analysts expect that Jazz Pharmaceuticals PLC will post $11.01 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Jazz Pharmaceuticals PLC (JAZZ) Given a $182.00 Price Target at Piper Jaffray Companies” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/15/jazz-pharmaceuticals-plc-jazz-stock-rating-reaffirmed-by-piper-jaffray-companies.html.

In other Jazz Pharmaceuticals PLC news, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $150.65, for a total transaction of $30,130.00. Following the transaction, the executive vice president now owns 22,223 shares in the company, valued at $3,347,894.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 2,500 shares of the stock in a transaction that occurred on Thursday, April 27th. The stock was sold at an average price of $160.00, for a total value of $400,000.00. Following the transaction, the executive vice president now owns 39,649 shares in the company, valued at approximately $6,343,840. The disclosure for this sale can be found here. Insiders have sold 42,095 shares of company stock worth $6,486,026 in the last quarter. 4.30% of the stock is currently owned by company insiders.

A number of institutional investors have recently modified their holdings of JAZZ. Envestnet Asset Management Inc. increased its position in shares of Jazz Pharmaceuticals PLC by 43.0% in the first quarter. Envestnet Asset Management Inc. now owns 981 shares of the specialty pharmaceutical company’s stock worth $141,000 after buying an additional 295 shares in the last quarter. World Asset Management Inc acquired a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $205,000. Bridges Investment Management Inc. acquired a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $208,000. Private Advisor Group LLC acquired a new position in shares of Jazz Pharmaceuticals PLC during the first quarter worth about $215,000. Finally, Mn Services Vermogensbeheer B.V. increased its position in shares of Jazz Pharmaceuticals PLC by 2.8% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 1,601 shares of the specialty pharmaceutical company’s stock worth $217,000 after buying an additional 44 shares in the last quarter. Institutional investors own 85.91% of the company’s stock.

Jazz Pharmaceuticals PLC Company Profile

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.